GlassScriptPhysician profile
Lisa A Brown
NPI 1063815587
$652.54
in general payments reported to CMS, 2019-2025
20 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $14.33 · 2023: $35.40 · 2024: $313 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $136.63 | 2021-2025 | |
| Lilly USA, LLC | $66.13 | 2021-2024 | Mounjaro, Jardiance |
| Dexcom, INC. | $43.97 | 2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $42.25 | 2021-2024 | Breztri |
| Exact Sciences Corporation | $39.04 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $36.99 | 2021 | |
| Vanda Pharmaceuticals INC. | $36.38 | 2024 | Hetlioz, Fanapt |
| Novo Nordisk INC | $31.54 | 2021-2023 | Rybelsus, Ozempic |
| Corium, LLC | $31.06 | 2024 | Azstarys |
| Pacira Pharmaceuticals Incorporated | $27.33 | 2024 | Exparel, Zilretta |
| Xeris Pharmaceuticals, INC. | $20.36 | 2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $17.65 | 2025 | |
| Cranial Technologies, INC | $17.36 | 2025 | Doc Band |
| Biohaven Pharmaceuticals, INC. | $17.35 | 2021 | |
| Esperion Therapeutics, INC. | $16.57 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.56 | 2021 | |
| Genentech USA, INC. | $14.33 | 2022 | |
| Glaxosmithkline, LLC. | $14.06 | 2024 | Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.99 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $13.99 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.